Pazopanib Hydrochloride CAS 635702-64-6 Purity >99.0% (HPLC) API Factory

Short Description:

Chemical Name: Pazopanib Hydrochloride

CAS: 635702-64-6

Appearance: White to Slightly Yellow Powder

Purity: >99.0% (HPLC)

Tyrosine kinase receptor inhibitor for the treatment advanced renal cell carcinoma or advanced soft tissue sarcoma

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply with High Purity and Stable Quality
Chemical Name: Pazopanib Hydrochloride
CAS: 635702-64-6
Tyrosine kinase receptor inhibitor for the treatment advanced renal cell carcinoma or advanced soft tissue sarcoma who have received prior chemotherapy.
API High Quality, Commercial Production

Chemical Properties:

Chemical Name	Pazopanib Hydrochloride
Synonyms	Pazopanib HCl; GW786034 HCl; Votrient; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
CAS Number	635702-64-6
CAT Number	RF-API93
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C21H23N7O2S.ClH
Molecular Weight	473.987
Solubility	DMSO
Melting Point	300.0~304.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Slightly Yellow Powder
Identification	The infraed absorption spectrum of the test sample is concordant with that of the standard
Residue on Ignition	≤0.50%
Any Individual Impurity	≤0.30%
Total Impurities	≤1.50%
Heavy Metals	≤10ppm
Purity / Analysis Method	≥99.0% (HPLC)
Test Standard	Enterprise Standard
Usage	API, Tyrosine kinase receptor inhibitor

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Pazopanib Hydrochloride (CAS 635702-64-6) is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (cFms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-beta receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice. It was approved for renal cell carcinoma by the U.S. Food and Drug Administration in 2009 and is marketed under the trade name Votrient by the drug’s manufacturer, GlaxoSmithKline. Votrient is a kinase inhibitor indicated for the treatment of patients with: 1) advanced renal cell carcinoma. 2) advanced soft tissue sarcoma who have received prior chemotherapy.